VIM and melanoma: However, our analysis of an independent study by Parmenter et al. [37] showed that after Vemurafenib treatment, TPC2 is overexpressed, while YAP/TAZ target genes are down regulated as well as ZEB1 and Vimentin, confirming our data in a different model of melanoma.